Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D Life Science Investing
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference Life Science Investing
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC Life Science Investing
PADCEV Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Pharmaceutical Investing
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients Life Science Investing
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California Life Science Investing
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Life Science Investing
